A major artificial intelligence firm is pushing its ambitions into drug science, even as its own staff warn that AI could justify "erasing jobs and possibly human life." Anthropic, an AI startup, has quietly established a wet lab in the San Francisco Bay Area, moving beyond computer simulations to conduct physical experiments.
Eric Kauderer-Abrams, Anthropic’s head of life sciences, confirmed the new facility in a Reuters interview just four days ago. He stated that "to do biology, the final test is still and will be for a while in real lab work." This physical expansion marks a significant step for a company whose CEO, Dario Amodei, has called for a development slowdown, citing the potential for catastrophic damage from advanced AI.
The Human Cost
One source familiar with Anthropic's efforts revealed the company is trying to achieve its goals before the public loses faith that AI justifies the displacement of workers and the potential loss of human life. Some Anthropic researchers have explicitly warned that AI could lead to human extinction. The company itself has found instances where its systems might be used for biological weapons development, a claim that met some skepticism.
Amodei, whose father died from a disease shortly before a cure emerged, stated in a recent essay that the effort is personal. Kauderer-Abrams echoed this, saying the company's mission is "to develop powerful AI in such a way that benefits the world." He added that life sciences represent the biggest opportunity for this global benefit, motivating all their work.
Elite Ambition, Global Reach
Anthropic is embracing physical automation, aiming for its Claude AI to direct robotic units in science experiments with limited human intervention. A spokesperson insisted human oversight remains essential for safety. Kauderer-Abrams called this "the very early innings of using AI to automate the execution of lab work," predicting it could bring "meaningful acceleration in so many different processes."
Despite warnings about AI's potential for harm, Anthropic is preparing for a potentially $2 trillion IPO to raise more capital for AI development. Kauderer-Abrams noted they are "always balancing these things," striving to make models better for medicine while being careful about deployment to limit risk.
At a San Francisco event in June of the same year, Anthropic announced its intention to run drug programs, focusing on preclinical work in areas traditional companies found financially unattractive. The company also launched Claude Science software. It previously added Novartis CEO Vas Narasimhan to its board and acquired Coefficient Bio for approximately $400 million in stock, a move confirmed by Anthropic to build drug development tools.
The New Frontier of Control
Anthropic is now bulking up its in-house lab efforts for speed and firsthand experience, though it outsources work when efficient. Kauderer-Abrams told Reuters they can do some things "much faster in our own hands," with the goal "to operate at the largest possible scale." Recent job postings, including one for a leader to ramp up procurement, reveal the company's aggressive expansion. Another listing sought an expert on protein and nucleic acid characterization, while a third declared: "Our goal is to speed up progress in the life sciences by an order of magnitude."
Life sciences already constitute one of Anthropic’s largest investment areas by headcount and resources. Kauderer-Abrams believes AI could fast-track development for conditions previously thought to be undruggable, speeding discovery of complex molecules like bispecific and trispecific antibodies. The precise diseases Anthropic is targeting and its progress remain undisclosed.
In August of the same year, Anthropic launched the Model Hardware Standard to help AI operate equipment. The company provides AI services and tools to top pharmaceutical corporations, including Roche’s Genentech, Bristol Myers Squibb, and Novo Nordisk. Anthropic is also navigating a "trust problem" with customers who worry the AI firm might learn from their competing drug programs, even as it walls off their data. Kauderer-Abrams maintains they are "not competing with pharma and biotech companies that make their business in bringing drugs to market," focusing on needs the industry won't address. This transnational collaboration further solidifies the elite's grip on critical life sciences, with unknown long-term consequences for national health systems and the native working class.